Our patent, titled “Type I and Type III Interferon Fusion Molecules and Methods for Use Thereof” (US 11,292,823), has received approval in Japan.
September 2024
Targeron submitted its First STTR application entitled Bi-specific Phosphatidylserine Targeting Type I/Type III Interferon Fusion Proteins for Immune Oncology Applications on September 5th, 2024.
May 2024
Targeron Therapeutics was awarded an NJ Innovation and Research Fellowship Grant from the New Jersey Department of Labor in May of 2024.
Contact us with inquiries or to schedule an introductory call.
